标题
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
作者
关键词
Metastatic breast cancer, Cyclin-dependent kinases 4 and 6, Clinical trials, Resistance mechanisms, Palbociclib, Ribociclib, Abemaciclib
出版物
Current Oncology Reports
Volume 21, Issue 3, Pages -
出版商
Springer Nature
发表日期
2019-02-26
DOI
10.1007/s11912-019-0769-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3
- (2018) Dennis J. Slamon et al. JOURNAL OF CLINICAL ONCOLOGY
- Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
- (2018) Debu Tripathy et al. LANCET ONCOLOGY
- The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial
- (2018) Ben O'Leary et al. Cancer Discovery
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer
- (2016) Maria Teresa Herrera-Abreu et al. CANCER RESEARCH
- Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
- (2016) John F R Robertson et al. LANCET
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Palbociclib in Combination With Fulvestrant in Women With Hormone Receptor-Positive/HER2-Negative Advanced Metastatic Breast Cancer: Detailed Safety Analysis From a Multicenter, Randomized, Placebo-Controlled, Phase III Study (PALOMA-3)
- (2016) Sunil Verma et al. ONCOLOGIST
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells
- (2012) C. E. Caldon et al. MOLECULAR CANCER THERAPEUTICS
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cell cycle
- (2011) T. Hunt et al. PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now